Clinical trials: TACE
Hepatocellular Carcinoma (HCC)
TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with Tislelizumab and Lenvatinib in patients with advanced-stage hepatocellular carcinoma (HCC).
- Trial name
- CHANCE2602 (NCT07836309)
- Where
- China
- Volunteers
- 596 people
- Sponsor
- Zhongda Hospital
Resectable Hepatocellular Carcinoma
AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
This is a Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable hepatocellular carcinoma.
- Trial name
- NCT05578430
- Testing
- Cadonilimab, TACE, Surgery
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Diffuse Large B-Cell Lymphoma, Relapsed and Refractory
Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Current exploration of local therapies for large Diffuse Large B-Cell Lymphoma (DLBCL) masses remains in its infancy. This study aims to retrospectively evaluate the safety, efficacy, and tolerability of Drug-Eluting Bead-Based…
- Conditions
- Diffuse Large B-Cell Lymphoma, Relapsed and Refractory, Transarterial Chemoembolization
- Trial name
- NCT07198230
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ting YANG
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma
This Phase Ia study evaluated the safety and tolerability of a single escalating dose via intravenous infusion of the autologous invariant natural killer T cells (iNKT-cell) product GKL-006 in combination with transarterial…
- Trial name
- NCT07845266
- Testing
- GKL-006 Injection, transarterial chemoembolization
- Where
- 2 sites in China
- Volunteers
- 13 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Metastatic Colorectal Carcinoma, Multi-organ Metastatic Colorectal Cancer
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases
The purpose of this study was to investigate the effect of only local radical treatment of liver metastases combined with systematic treatment in the treatment of patients with multiple organ metastases of colorectal cancer…
- Conditions
- Metastatic Colorectal Carcinoma, Multi-organ Metastatic Colorectal Cancer, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT06449937
- Testing
- Radical local Surgery, Systemic therapy, Interventional therapy
- Where
- 6 sites in China
- Volunteers
- 130 people
- Sponsor
- Anhui Provincial Hospital
Unresectable Intrahepatic Cholangiocarcinoma
Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma
The goal of this clinical trial is to learn about the combined therapy using drug-eluting bead-transarterial chemoembolization (D-TACE), gemcitabine (Gem) and cisplatin (Cis) chemotherapy, and PD-1 antibody in patients with…
- Trial name
- NCT05738057
- Testing
- Camrelizumab, Gemcitabine Injection, Cisplatin injection
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Hua Li
Hepato Cellular Carcinoma
Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE
Conventional transarterial chemoembolization with Doxorubicin (c-TACE) is the gold standard treatment for Hepato Cellular Carcinoma (HCC) stage B (BCLC) / stages A and B (Child-Pugh).
- Trial name
- CineDoxo (NCT03706157)
- Testing
- Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media, Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Strasbourg, France
Liver, Cancer of, Primary Resectable
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
This Randomized Controlled Trial was to clarity the clinical feasibility of 3D-HDRA results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.
- Trial name
- NCT05701436
- Testing
- Oxaliplatin, Doxorubicin, Lobaplatin
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Zhujiang Hospital
Healthy Volunteers
Recruiting Blood Donor With Allogeneic Natural Killer Cell
This study on manufacture of MG4101 (allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) after Transarterial Chemoembolization(TACE) will be harvested WBC(white blood cell) and plasma from healthy donors, or…
- Trial name
- NCT02716571
- Testing
- Leukapheresis or Plasmapheresis
- Where
- South Korea
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Carcinoma, Hepatocellular
Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas
The purpose of this study is to determine the maximal tolerated dose of idarubicin for chemoembolization of non resectable non metastatic hepatocellular carcinoma.
- Trial name
- NCT01040559
- Testing
- idarubicin
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Hepatocellular Carcinoma
LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)
The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearls for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE…
- Trial name
- NCT03053596
- Testing
- DEB-TACE using anthracyclin loaded LifePearl™
- Where
- 7 sites in Belgium, France
- Volunteers
- 102 people
- Sponsor
- Terumo Europe N.V.
Unresectable Hepatocellular Carcinoma
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
The goal of this clinical trial is to evaluate the efficacy and safety of NRT6003 Injection compared to cTACE in patients with unresectable HCC.
- Trial name
- CHEERS (NCT06900543)
- Testing
- NRT6003 Injection, cTACE
- Where
- 19 sites in China
- Volunteers
- 108 people
- Sponsor
- Chengdu New Radiomedicine Technology Co. LTD.
Tumor Response Rate, Overall Survival
TILA-TACE in Treatment of Hepatocellular Carcinoma
To validate the tumor response rate: in the previous study, the investigators showed that TILA-TACE achieved 100% tumor response rate.
- Trial name
- NCT03910140
- Testing
- TILA-TACE treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization
The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE
The purpose of this randomized, double-blind trial was to compare the effects of preemptive Oxycodone and sufentanil at the same dose on pain and inflammatory response after transcatheter arterial chemoembolization (TACE) of…
- Conditions
- Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Pain, Inflammation
- Trial name
- NCT06041425
- Testing
- Oxycodone, Sufentanil
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatocellular Carcinoma (HCC)
AI Multitask Model for HCC Treatment
We will integrate multi-modal cardiac data via an AI multitask framework to develop and validate concurrent models for liver function, treatment prognosis, and microvascular invasion (MVI) prediction in hepatocellular carcinoma.
- Trial name
- NCT07157085
- Testing
- Comprehensive treatment
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC)
TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
The safety, clinical efficacy and prognostic factors of transcatheter arterial chemoembolization (TACE) and/or hepatic artery infusion chemotherapy (HAIC) combined with targeted immunotherapy for primary hepatocellular carcinoma…
- Trial name
- NCT07658833
- Testing
- TACE (transarterial chemoembolization) combined with targeted/immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma
Pharmacogenetic Study in Hepatocellular Carcinoma Patients.
evaluate the prognostic value of genetic polymorphisms in HCC Egyptian patients undergoing TACE using lipiodol and doxorubicin.
- Trial name
- NCT05291338
- Testing
- Doxorubicin, Lipiodol
- Where
- Egypt
- Volunteers
- 107 people
- Sponsor
- Rehab Werida
Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion
According to radiology imaging, the patients of HCC are divided into two groups(hypovascular tumor group and moderately vascular tumor group).
- Trial name
- NCT00826384
- Testing
- balloon catheter
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)
To evaluate the time to progression of the combination therapy of Transcatheter Arterial Chemoembolization (TACE) and sorafenib in patients with previously untreated advanced or metastatic hepatocellular carcinoma.
- Trial name
- NCT01170104
- Testing
- Sorafenib, TACE (Transcatheter arterial chemoembolization)
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Chung-Ang University
Liver Cancer, Metastatic Cancer
Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer
RATIONALE: Learning about quality of life in patients with cancer undergoing embolization may help doctors learn about the side effects of treatment and plan the best treatment.
- Trial name
- NCT00739167
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Northwestern University